Compare TGE & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TGE | IFRX |
|---|---|---|
| Founded | 2023 | 2007 |
| Country | France | Germany |
| Employees | N/A | N/A |
| Industry | Newspapers/Magazines | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.4M | 67.0M |
| IPO Year | N/A | 2017 |
| Metric | TGE | IFRX |
|---|---|---|
| Price | $1.65 | $1.03 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 125.1K | ★ 635.9K |
| Earning Date | 10-20-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.48 | N/A |
| Revenue | ★ $130,212,000.00 | $73,729.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,054.36 |
| P/E Ratio | $3.36 | ★ N/A |
| Revenue Growth | ★ 316.50 | N/A |
| 52 Week Low | $0.78 | $0.71 |
| 52 Week High | $37.02 | $2.77 |
| Indicator | TGE | IFRX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 47.91 |
| Support Level | N/A | $0.93 |
| Resistance Level | N/A | $1.10 |
| Average True Range (ATR) | 0.00 | 0.08 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 0.00 | 39.40 |
The Generation Essentials Group is a media and entertainment company. Its publications L'Officiel and The Art Newspaper publish print editions in a total of nearly 28 countries and territories and digital contents. It operate in the movie production sector having produced various Asia-focused movies. It operate in three operating segments: media and entertainment segment, hotel operations, hospitality and VIP services segment and strategic investment segment. Key revenue is generated from strategic investment segment that is engage in proprietary investments and management of portfolio, including listed and unlisted equity shares investments and movie income right investments.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.